Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quest launches "quicker" HIV tropism test in US

This article was originally published in Clinica

Executive Summary

Quest Diagnostics has launched its HIV-1 coreceptor tropism test, to determine whether HIV patients will respond to CCR5-targeting drugs, as a lab service in the US. The Madison, New Jersey firm claims its test provides results in "half the time of the nearest competing test", Monogram Biosciences' Trofile (seven versus 14 days). Both tests identify which coreceptor a patient's HIV virus uses to enter human CD4 cells – CCR5, CXCR4, or a combination. This is known as the patient's "tropism". CCR5 antagonists, such as Pfizer's Selzentry (maraviroc), block the CCR5 coreceptor and therefore HIV entry, but only in CCR5-tropic patients. Trofile was launched in the US in August 2007.

You may also be interested in...

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

EuroPCR: Medtronic's drug-coated balloon keeps rising

A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts